

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

{CARDBOARD BOX}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ENURACE 50, 50 mg tablets for dogs
(Ephedrine HCl)

2. STATEMENT OF ACTIVE SUBSTANCES

Per tablet 50 mg ephedrine HCl.

3. PHARMACEUTICAL FORM

Tablets.

4. PACKAGE SIZE

100 tablets.

5. TARGET SPECIES

Dog

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral, with food. 1-3 mg/kg/day divided in 2 doses.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

9. SPECIAL WARNING(S), IF NECESSARY

Accidental ingestion by man, especially children, is dangerous. Read the package leaflet before use.

10. EXPIRY DATE

EXP month/year

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Store in the original package.
Divided tablets should be returned in the original package and used in the subsequent dose. Close the cap to the click.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

16. MARKETING AUTHORISATION NUMBER(S)

Vm 32742/4002

17. MANUFACTURER’S BATCH NUMBER

Lot

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

{POLYPROPYLENE CONTAINER}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ENURACE 50, 50 mg tablets for dogs
(Ephedrine HCl)

2. STATEMENT OF ACTIVE SUBSTANCES

Per tablet 50 mg ephedrine HCl.

3. PHARMACEUTICAL FORM

Tablets.

4. PACKAGE SIZE

100 tablets

5. TARGET SPECIES

Dog

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

9. SPECIAL WARNING(S), IF NECESSARY

Accidental ingestion by man, especially children, is dangerous. Close the cap to the click. Read the package leaflet before use.

10. EXPIRY DATE

EXP month/year

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Store in the original container.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

16. MARKETING AUTHORISATION NUMBER(S)

Vm 32742/4002

17. MANUFACTURER’S BATCH NUMBER

Lot

B. PACKAGE LEAFLET

PACKAGE LEAFLET:

ENURACE 50, 50 mg tablets for dogs

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

Manufacturer responsible for batch release:

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

ACE Pharmaceuticals BV
Schepenveld 41
3891 ZK Zeewolde
The Netherlands

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

ENURACE 50, 50 mg tablets for dogs
(Ephedrine HCl)

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

The product contains 50 mg ephedrine HCl per tablet, corresponding with 40.7 mg ephedrine. The tablet can be divided in two equal parts, each part containing 25 mg ephedrine HCl.

4. INDICATION(S)

Treatment of unwanted loss of urine (urinary incontinence) due to too low tension in the circular muscles closing the urethra (urethral sphincter mechanism incompetence) in ovariohysterectomised female dogs.

5. CONTRAINDICATIONS

Do not use the product in dogs with increased pressure in the eye (glaucoma).
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. ADVERSE REACTIONS

- Disorders of the heart and blood circulation (tachycardia, atrium fibrillation, stimulation of the heart activity; vasoconstriction).
- Stimulation of the central nervous system, leading to sleeplessness, excitation, anxiety and trembling of the muscles (muscle tremors).
- Panting.
- Dilatation of the pupils (mydriasis).
- Bladder infection (cystitis).
- Relaxation of the muscles of the lungs (bronchodilatation) and decrease of mucus release in the lungs (respiratory mucosal membranes).
- Reduction of the motion (motility) and tension (tone) of the intestinal wall.

Due to the nature of ephedrine the above-mentioned effects can occur at the recommended therapeutic dose, with anxiety and cardiovascular effects being the most prevalent. In 10% of the treatments, side effects have been observed in efficacy studies.

Vomiting has been reported very rarely in spontaneous reports.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Ovariohysterectomised female dogs.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral administration only.

Give a starting dose of 2 mg ephedrine HCl / kg / day, divided in two oral doses.

Dose according to the following dosing scheme:

Weight (kg)	Dose (mg/day)	Dose (Number of tablets)		
		per day	1 st gift	2 nd gift
20-30	50	1	½	½
31-40	75	1 ½	½	1
41-50	100	2	1	1

Desired therapeutic effect and occurrence of adverse effects have to be monitored approximately at 14 days, 1 month, 3 months and 6 months after the start. Based on the observed effect in comparison with the expected effect and taking into account

the occurrence of adverse effects, the individual dose should be adjusted. The dose should be adjusted to find the lowest effective dose. Once the effective dose has been established, dogs should still be monitored at regular intervals, e.g. every six months.

The product should be administered before meals in a piece of food.

A maximum dose of 5 mg/ kg of bodyweight per day has to be respected.

9. ADVICE ON CORRECT ADMINISTRATION

Pregnant women should wear gloves.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Do not store above 25°C.

Store in the original container.

Return divided tablet in the original package and use this tablet in the subsequent dose. Close the cap to the click.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after "EXP". The expiry date refers to the last day of that month.

12. SPECIAL WARNING(S)

Special warnings for each target species:

This product is not suitable for treatment of inappropriate urination due to behaviour problems.

Special precautions for use in animals:

Do not use the product in dogs under 20 kg bodyweight.

As ephedrine is an alpha- and beta-adrenergic receptor agonist, the product should be used with caution in dogs with cardiovascular disease and only after a comprehensive risk/benefit analysis by the attending veterinarian.

The dog's cardiovascular functionality should be carefully assessed before the start of the treatment with the product and it should be periodically monitored during the treatment.

In addition, a similar approach should be adopted in animals suffering from partial urethral obstruction, hypertension, diabetes mellitus, hyperadrenocorticism, hyperthyroidism or other metabolic disorders. It should be mentioned that the polyuria/polydipsia (PU/PD) frequently accompanying the aforementioned conditions may be falsely diagnosed as urinary incontinence.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

It is strongly recommended that pregnant women should wear gloves for administration.

Wash hands after administration.

Warnings on accidental ingestion

Ephedrine hydrochloride could be toxic if ingested. Adverse effects may include insomnia and nervousness, dizziness, headache, increased blood pressure, increased sweating and nausea.

Ingestion may be fatal, especially in children. To avoid accidental ingestion, the product must be used and kept out of the reach of children. Always replace the cap securely after use.

In the event of accidental ingestion, most importantly by children, seek immediate medical attention showing the physician the package insert.

Interaction with other medicinal products and other forms of interaction:

- Ephedrine may interact with other sympathomimetics.
- Ephedrine may enhance the metabolism of hormones of the pituitary gland (glucocorticoid metabolism).
- Concomitant use with MAO-inhibitors (used for treatment of depression) may cause increased blood pressure (hypertension).
- Ephedrine can enhance the activity of products of the same class as theophylline (used in treatment of epilepsy).
- Volatile anaesthetics may enhance the sensitivity of the heart muscle (myocardium) to the effects on heart and blood vessels (cardiovascular effects) of ephedrine.
- Concomitant use with cardiac glycosides (used to increase the pump force of the heart), quinine (anti-infection) and tricyclic antidepressants (used for treatment of depressions) can cause disorders of the heart rhythm (arrhythmias).
- Constrictions of the blood vessels (vascular constrictions) can occur after concomitant treatment with ergot alkaloids and oxytocin (both used for the induction of labour).
- Substances leading to an increase in pH of the urine are able to prolong the excretion of ephedrine, whereas substances leading to a decrease in pH of the urine are able to accelerate the excretion of ephedrine.

Overdose (symptoms, emergency procedures, antidotes):

The signs of overdose resemble those of the adverse reactions as described in section 6. In case of overdose, it is useful to accelerate excretion of ephedrine by acidification of the urine and enhanced diuresis.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

September 2020

15. OTHER INFORMATION

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

A handwritten signature in black ink, consisting of several loops and a final horizontal stroke.

Approved: 10 November 2020